Hone Bio

Targeted lipid nanoparticles

  • Biotech
Therapeutics

Member

Active

Status

2017

Founded

Seed

Development stage

  • SCVC
    Old Market
    Incubator residents

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.

Founding team

Key contacts

Senior Protein Scientist

Senior Research Scientist